Shanghai Pharmaceuticals Holding (601607) Stock Price, Fundamentals & Analysis

What 601607 does

Shanghai Pharmaceuticals Holding (601607) is a stock listed on the Shanghai Stock Exchange stocks that operates across the pharmaceutical value chain in China and internationally. The company researches, develops, manufactures, and sells chemical and biological drugs, Chinese medicine, healthcare products, and medical devices, while also running a network of retail pharmacy stores. Its four business segments — Production, Distribution, Retail, and Others — cover everything from manufacturing to warehousing, logistics, and supply-chain services for hospitals, distributors, and pharmacies. With 48,640 employees and headquarters in Shanghai, China, the company is part of the Healthcare sector and the Medical Distribution industry. It is also a component of the CSI 300 index.

Key numbers explained

• The current price is 16.02 CNY, down 0.25% today, with a 52-week range of 15.01 – 18.56 and a year-over-year decline of -10.2%.
• The trailing P/E ratio of 12.4 shows how much investors pay per unit of recent earnings; the forward P/E ratio of 10.4 uses expected future earnings and is typically read as a more optimistic gauge.
• The dividend yield of 2.81% tells you the annual cash return relative to the share price, with 32% of earnings paid out as dividends and an ex-dividend date of 18 sept. 2026.
• Earnings per share (trailing 12 months) stands at 1.29 CNY, while the price-to-book ratio of 0.76 suggests the stock trades below its book value.
• The beta of 0.15 indicates the stock historically moves much less than the overall market, and the debt-to-equity ratio of 63.5% shows the level of debt relative to shareholders' equity.
• On the income side, revenue (trailing 12 months) is 289.46 mld. CNY, growing 1.9% year over year, with a profit margin of 1.6% and an operating margin of 3.6%.
• The return on equity of 7% measures how effectively the company generates profit from shareholders' capital.

What to watch

Shanghai Pharmaceuticals Holding (601607) operates in a sector that is sensitive to healthcare policy, drug pricing reforms, and public health demand in China. Investors in Medical Distribution stocks like this one often monitor changes in government procurement rules, reimbursement policies, and the competitive landscape among peers such as Fosun Pharmaceutical (600196), Beijing Tongrentang (600085), and Guangzhou Baiyunshan Pharmaceutical Holdings (600332). Broader factors include regulatory approvals, supply-chain stability, and the performance of the retail pharmacy segment. The stock's low beta of 0.15 may appeal to those seeking less volatile exposure, while its dividend yield of 2.81% and ex-dividend date of 18 sept. 2026 are relevant for income-focused investors.